S&P500 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? S&P500 ETF trades at $771.54, while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). Which is the better fit depends on your goals.
| SPY | VRTX | |
|---|---|---|
52-Week High | $773.22 | $529.65 |
52-Week Low | $631.99 | $376.62 |
Market Cap | — | $132.79B |
Sector | — | Health |
Enterprise Value | — | $126.92B |
Signals from Pluang's Aura AI — not financial advice
SPY, the SPDR S&P 500 ETF, trades at $773.22, up 0.6% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and benefits from robust S&P 500 earnings growth, though RSI indicates short-term overbought conditions. A dividend of $1.90 is scheduled for July 2026, adding income appeal.
Outlook remains positive with JPMorgan raising its S&P 500 target to 8,000, driven by AI-driven earnings. Risks include high valuations and potential pullbacks from overbought levels. Investors should weigh long-term growth against near-term volatility.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Trailing returns across standard periods
Latest headlines on both assets
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →